• HexaCard is an innovative service to improve quality control in cell characterization for bioproduction, cell and gene therapy applications
• HexaCard offers a highly accurate analytical method for characterizing transformed cell lines, with the ability to assess six critical parameters in a single assay
• HexaCard helps identify transgene stability, cell clonality and provides a unique genetic identity card for each clone or batch, ensuring accuracy across the entire production pipeline
Bagneux (France) – Genomic Vision (FR0011799907 – GV, the “Company”), a biotechnology company listed on Euronext developing products and services for the precise characterization of DNA sequences, is pleased to announce the launch of its new service, HexaCard.
If you wish to receive all of the company’s financial communications in real time, you can register directly by email at the following address: [email protected]